SYDNEY, Australia—Australian biotech group Innate Immunotherapeutics Limited said on Thursday it was not under investigation in an insider trading case involving Republican U.S. congressman Christopher Collins.
In a statement, the company said it had cooperated fully with requests for information from the U.S. Securities and Exchange Commission (SEC).
